Early and Sustained Improvements in Sense of Smell With Tezepelumab Treatment in Patients With Chronic Rhinosinusitis With Nasal Polyps (WAYPOINT).

Saved in:
Bibliographic Details
Title: Early and Sustained Improvements in Sense of Smell With Tezepelumab Treatment in Patients With Chronic Rhinosinusitis With Nasal Polyps (WAYPOINT).
Authors: Mullol J; Rhinology Unit & Smell Clinic, Department of Otorhinolaryngology, Hospital Clinic Barcelona, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Catalonia, Spain., Han JK; Department of Otolaryngology, Head and Neck Surgery, Eastern Virginia Medical School, Norfolk, Virginia, USA., Laidlaw TM; Division of Allergy and Clinical Immunology, Department of Medicine, Jeff and Penny Vinik Center for Translational Immunology Research, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Hopkins C; Department of Otolaryngology-Head and Neck Surgery, Guy's and St Thomas' Hospital, London, UK., Peters AT; Division of Allergy and Immunology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA., Pfaar O; Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps University of Marburg, Marburg, Germany., Desrosiers M; Division of Otolaryngology, Head and Neck Surgery, Centre Hospitalier de L'Université de Montréal, University of Montreal, Montreal, Quebec, Canada., Lee SE; Division of Otolaryngology, Head and Neck Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Lane AP; Department of Otolaryngology, Head and Neck Surgery, Johns Hopkins School of Medicine, Baltimore, Maryland, USA., Chen C; Biometrics, Late-stage Development, Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Maryland, USA., Chon Y; Global Biostatistical Science, Amgen, Thousand Oaks, California, USA., Ponnarambil SS; Late-stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Foster A; Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Maryland, USA., Lindsley AW; US Medical Affairs, Amgen, Thousand Oaks, California, USA., Ambrose CS; Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Maryland, USA.
Source: International forum of allergy & rhinology [Int Forum Allergy Rhinol] 2026 May; Vol. 16 (5), pp. 484-494. Date of Electronic Publication: 2026 Jan 06.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study
Journal Info: Publisher: Published for ARS-AAOA by Wiley-Blackwell Country of Publication: United States NLM ID: 101550261 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2042-6984 (Electronic) Linking ISSN: 20426976 NLM ISO Abbreviation: Int Forum Allergy Rhinol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2042-6984
DOI:10.1002/alr.70090